[Analysis for the breast cancer screening among urban populations in China, 2012-2013].

Zhonghua Yu Fang Yi Xue Za Zhi

Department of Epidemiology, Harbin Medical University School of Public Health, Harbin 150081, China; #National Cancer Center, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Program Office for Cancer Screeming in Urban China, Beijing 100021, China.

Published: October 2016

To analyze results of breast cancer screenings in the Cancer Screening Program in Urban China(CanSPUC)during 2012-2013. In 14 cities of 9 provinces(Eastern Region: Beijing, Hebei, Liaoning, Shandong and Guangdong; Central Region: Heilongjiang and Hunan; Western Region: Chongqing and Gansu), 198 097 women aged 40-69 years who had lived in their cities for ≥3 years were surveyed through a cancer risk assessment questionnaire during 2012-2013. The questionnaires identified women considered to be at high risk for breast cancer, of whom 17 104 received screening examinations, for whom complete records of breast cancer screening and other data were available for 12 440 subjects altogether, including breast ultrasound exams for subjects 40-44 years old. Subjects older than 45 years or in whom breast imaging reporting and data system(BI-RADS)ultrasound had found ≥ 3 lesions also underwent mammography. In this cohort, BI-RADS 3 class was defined as suspicious and BI-RADS ≥4 class as positive. Chi-square tests were used to compare breast cancer screening results by groups. As of October 2013, breast cancer screening percentages for the 12 440 subjects for whom full data were available were, by region, Eastern: 55.43%(6 895); Central: 21.45%(2 669); and Western: 23.12%(2 876); by age, 40-44 years: 5.50%(684); ≥45 years: 94.50%(11 756). Using BI-RADS, 2018 subjects were found to have 3 lesions(detection rate: 16.22%), which were distributed regionally as Eastern: 19.00%(1 310 women), Central: 13.75%(367)and Western; 11.86%(341); χ=91.45, 0.001; and 289 were found to have ≥4 lesions(detection rate: 2.32%), which were distributed regionally as Eastern: 2.41%(166), Central: 1.54%(41)and Western; 2.85%(82); χ=11.04, 0.004. Women aged 50-54 years had the highest detection rate of BI-RADS 3 lesions at 18.74%(561/2 994), and those aged 40-44 years had the highest detection rate of BI-RADS ≥4 at 2.92%(20/684). Detection rates of BI-RADS ≥4 lesions were highest in the Western region and in women aged 40-44 years, and lowest in the Central region and in women aged 60-64 years. Detection rates of BI-RADS 3 lesions were highest in the Eastern region and in women aged 50-54 years and the lowest in the Western region and in women aged 60-64 years.

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-9624.2016.10.010DOI Listing

Publication Analysis

Top Keywords

breast cancer
24
women aged
24
cancer screening
20
40-44 years
16
region women
16
western region
12
years
12
bi-rads ≥4
12
cancer
8
region
8

Similar Publications

Leaky and structurally abnormal blood vessels and increased pressure in the tumor interstitium reduce the infiltration of CAR-T cells in solid tumors, including triple-negative breast cancer (TNBC). Furthermore, high burden of tumor cells may cause reduction of infiltrating CAR-T cells and their functional exhaustion. In this study, various effector-to-target (E:T) ratio experiments are established to model the treatment using CAR-T cells in leukemia (high E:T ratio) and solid tumor (low E:T ratio).

View Article and Find Full Text PDF

In triple-negative breast cancer (TNBC), pro-tumoral macrophages promote metastasis and suppress the immune response. To target these cells, a previously identified CD206 (mannose receptor)-binding peptide, mUNO was engineered to enhance its affinity and proteolytic stability. The new rationally designed peptide, MACTIDE, includes a trypsin inhibitor loop, from the Sunflower Trypsin Inhibitor-I.

View Article and Find Full Text PDF

Breast cancer is the most common malignancy among women. While advances in detection and treatment have improved survival, breast cancer survivors face an increased risk of cardiovascular disease. However, limited data exist on cardiac outcomes after ST-elevation myocardial infarction (STEMI) in this population.

View Article and Find Full Text PDF

An on-Demand Oxygen Nano-vehicle Sensitizing Protein and Nucleic Acid Drug Augment Immunotherapy.

Adv Mater

January 2025

State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute. Ren Ji Hospital School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, P. R. China.

Hypoxia severely limits the antitumor immunotherapy for breast cancer. Although efforts to alleviate tumor hypoxia and drug delivery using diverse nanostructures achieve promising results, the creation of a versatile controllable oxygen-releasing nano-platform for co-delivery with immunostimulatory molecules remains a persistent challenge. To address this problem, a versatile oxygen controllable releasing vehicle PFOB@F127@PDA (PFPNPs) is developed, which effectively co-delivered either protein drug lactate oxidase (LOX) or nucleic acids drug unmethylated cytosine-phosphate-guanine oligonucleotide (CpG ODNs).

View Article and Find Full Text PDF

Therapeutic Black Phosphorus Nanosheets Elicit Neutrophil Response for Enhanced Tumor Suppression.

Adv Sci (Weinh)

January 2025

Department of General Surgery, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230036, P. R. China.

Black phosphorus (BP) has demonstrated potential as a drug carrier and photothermal agent in cancer therapy; however, its intrinsic functions in cancer treatment remain underexplored. This study investigates the immunomodulatory effects of polyethylene glycol-functionalized BP (BP-PEG) nanosheets in breast cancer models. Using immunocompetent mouse models-including 4T1 orthotopic BALB/c mice and MMTV-PyMT transgenic mice, it is found that BP-PEG significantly inhibits tumor growth and metastasis without directly inducing cytotoxicity in tumor cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!